FIGURE 8 from Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner

6B11 mAb-treated iNKT cells suppress tumor growth in vivo. A,E,G, Schematic of iNKT cell therapy in vivo. B–D, Human IL7/IL15 knockin NSG mice were subcutaneously injected with K562 cells on day 0. iNKT cells treated with the 6B11 mAb (50 ng/mL) or mIgG1(50 ng/mL) overnight were washed and resuspended in PBS. B, iNKT cells were intratumorally injected on days 3, 5, 7, and 9 (n = 6 or 7 mice/group). B and C, Tumor size was measured every 2 days. D, Tumors were excised at day 13 and their weight was measured. F, Human IL7/IL15 knock-in NSG mice were subcutaneously injected with K562 cells on day 0. iNKT cells treated with the 6B11 mAb as described in B were intratumorally or intravenously injected on days 3, 5, 7, and 9 (n = 5 or 6 mice/group). H, Human IL7/IL15 knock-in NSG mice were subcutaneously injected with K562 cells on day 0. iNKT cells treated with the 6B11 mAb as described in B or untreated iNKT cells were intratumorally injected on days 3, 5, 7, and 9 (n = 5 or 6 mice/group). The 6B11 mAb was further intraperitoneally administrated to mice injected with untreated NKT cells. Data are representative of two independent experiments. Data represent the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.